Illumina

RANK20

Long at the forefront of gene-sequencing and -therapy technology, Illumina is picking up steam thanks to the proliferation of DNA sequencing across a variety of medical applications—including tracking infectious diseases like COVID-19. Illumina says there are now some 70 countries using its tech to monitor and analyze samples of the coronavirus, hoping to track how it could mutate into variants. Just as Illumina has helped sharply reduce the cost of genetic sequencing, it aims to do the same for cancer diagnostics via its acquisition of biotech Grail (though the deal faces scrutiny from antitrust regulators).